In HR+ metastatic/recurrent #BreastCancer, co-use of PPIs or H2 blockers w/ CDK4/6 inhibitors was linked to worse PFS & OS in this study, needing caution when prescribing concomitant acid-suppressive therapy. @susanebates @gbanna74 @PasRescigno https://t.co/7gknEwilWm

Pre-existing and emerging immune-mediated diseases in patients with breast cancer undergoing cyclin-dependent kinases 4/6 inhibitors and endocrine therapy #BreastCancerAwarenessMonth @susanebates @PasRescigno @gbanna74 https://t.co/uKZlWqb6ny

Model Y Standard & Model 3 Standard are here

Deep learning radiomics model for non-invasive preoperative prediction of axillary lymph node metastasis in breast cancer supports diagnostic accuracy. #BreastCancerAwareness #AI @susanebates @gbanna74 @PasRescigno https://t.co/yUMQHHYdCq

This study highlights the predictive & prognostic value of #TILs in #HER2Positive #BreastCancer, showing improved pCR & DFS outcomes w/ high TIL levels. A step toward personalized neoadjuvant therapies! @susanebates @gbanna74 @PasRescigno https://t.co/LSqZJc715V

Predictors of advanced-stage presentation among patients with a diagnosis of breast and cervical cancer in Ethiopia #BreastCancerAwareness #GlobalHealth @susanebates @PasRescigno @gbanna74 https://t.co/2cN9GeVzIK

🧠 Can mindfulness support patients with metastatic renal cell carcinoma? Join The Oncologist’s eJournal Club on Thursday, October 30 from 6–7pm EDT for a live social media discussion, hosted by @realbowtiedoc. Joining instructions: https://t.co/oyy1UwLPH2

In early #BreastCancer adjuvant trials, invasive disease-free survival & invasive breast cancer-free survival correlated w/ OS, esp. in HR+/HER2– disease; distant disease-free survival was the best surrogate in TNBC. @susanebates @gbanna74 @PasRescigno https://t.co/7cwSOfmfwO

Huge thanks to our Deputy Editors @gbanna74 and @PasRescigno for proudly representing The Oncologist at #IUCS25 earlier this month. We’re grateful for your leadership!

⬆️ in #EOCRC (under 50) demands specialized programs. Study with 7 🇺🇸🇨🇦leaders propose a 10-step blueprint for development: Program manager for monitoring. Addresses unique needs #crcsm #GIonc @susanebates @gbanna74 @PasRescigno https://t.co/E4vab8Mesj

In this meta-analysis, #lenvatinib was found to increase the risk of hypertension (all-grade=50%, grade ≥3=14%) & proteinuria (all-grade=32%, grade ≥3=6%), esp. w/ high doses (≥20mg). Close monitoring is required. https://t.co/fMXEAzIAXl @susanebates @gbanna74 @PasRescigno

Review of the advantages & limitations of various #ctDNA detection strategies in oncology: 🧬PCR-based tests: Sensitive, cost-effective, but limited gene scope 🧬NGS: Broad genotyping & detects actionable mutations @susanebates @gbanna74 @PasRescigno https://t.co/rve6QFBY15

In patients with #melanoma (1–3 LN mets), selective LN dissection + adjuvant immunotherapy (IO) achieved a 2-yr RRFS of 65.7%, with low morbidity. This supports avoiding full LN dissection when feasible. @susanebates @gbanna74 @PasRescigno https://t.co/5Hjq9dHrq6

Across 9 studies involving patients with cT4 #ColonCancer, laparoscopic colectomy (LC) was linked to a higher risk of peritoneal recurrence vs open colectomy (OR 1.61; HR 1.24). #crcsm @susanebates @gbanna74 @PasRescigno https://t.co/EqM8ORUonu

#Durvalumab + gemcitabine/cisplatin significantly improved OS & PFS vs chemo alone across 10 studies (n=2877) in this meta-analysis on 1L therapy in advanced biliary tract cancer. #BTC #immunotherapy @susanebates @gbanna74 @PasRescigno https://t.co/8RZrnAHkMj

In this review of 22 studies involving older adults w/ cancer, #QoL was stable long-term but declined during treatment & last year of life. Comorbidities, older age, & mobility issues predicted decline. #gerionc #supponc @susanebates @gbanna74 @PasRescigno https://t.co/hi2oErURVm

In early-stage #TNBC, chemo+ICI achieved 50% pCR (vs 35.9% w/ chemo alone), albeit lower than #KEYNOTE522 trial rates. Less pronounced real-world benefit needs further validation in a larger cohort. #immunotherapy #bcsm @susanebates @gbanna74 @PasRescigno https://t.co/4SHRe5NPJB

In 6 🇹🇷 centers, #mCRPC pts treated with 177Lu-PSMA-617, prior #enzalutamide (vs #abiraterone) linked to ⬆️ PFS (7.6 vs 5.3 mo, P=0.068), ⬆️ OS (12.8 vs 6.9 mo, P=0.021) Sequencing is 🔑 #GUonc @susanebates @gbanna74 @PasRescigno https://t.co/5fVNT18vTP

2025 International Urology Cancer Summit #IUCS25 Abstracts @susanebates @gbanna74 @PasRescigno https://t.co/Fa1f99C85i

Low-dose methadone w/ ongoing opioid treatment shows potential efficacy in the management of refractory cancer pain w/ acceptable mild/moderate adverse events, making it a promising option. #PallOnc #SuppOnc #CancerPain @susanebates @gbanna74 @PasRescigno https://t.co/IwB3df8wFy

🚨Major findings on lung cancer care delays at Mexico's National Cancer Institute. 📊 Learn how treatment intervals have changed and which patients have worse outcomes. #Mexico #GlobalHealth #Cancer @susanebates @gbanna74 @PasRescigno https://t.co/gd2QOJ8sUS